PT-141: Research & Studies

Research Overview#

PT-141 (bremelanotide) has one of the most extensive clinical research programs of any peptide in the research peptide space. Unlike most peptides discussed on this site, which rely on preclinical data alone, PT-141 has completed Phase 3 clinical trials, received FDA approval, and has post-marketing safety surveillance data. This places it at the highest evidence tier among peptides reviewed here.

The clinical development program spanned multiple phases, beginning with early observations of sexual arousal effects during Melanotan-2 studies, progressing through dose-finding and mechanistic studies, culminating in the RECONNECT Phase 3 registration trials, and continuing with ongoing post-marketing studies and investigation of additional indications.

The RECONNECT Phase 3 Trials#

Study Design#

The pivotal evidence for PT-141's approval came from the RECONNECT program: two identical Phase 3, randomized, double-blind, placebo-controlled, multicenter clinical trials conducted at U.S. sites. Study 301 ran from January 2015 to July 2016, and Study 302 from January 2015 to August 2016.

Patient population: Premenopausal women ages 21-55 with acquired, generalized HSDD as defined by DSM-IV-TR criteria, diagnosed at least 6 months prior to enrollment.

Randomization: 2:1 bremelanotide 1.75 mg to placebo, self-administered subcutaneously as needed at least 45 minutes before anticipated sexual activity.

Primary endpoints:

1. Change from baseline in the number of satisfying sexual events (SSEs) per month
2. Change from baseline in desire domain score on the Female Sexual Function Index (FSFI)
3. Change from baseline in distress score on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO)

Key Efficacy Results#

The integrated results from both RECONNECT studies demonstrated:

The coprimary endpoints of sexual desire and distress related to low sexual desire were both statistically significant in both individual studies and in the integrated analysis. The number of satisfying sexual events also showed improvement but was a secondary endpoint.

Effect Size Considerations#

The effect sizes observed in RECONNECT were modest, which has been a point of discussion in the field. Several contextual factors are relevant:

• HSDD involves subjective experiences (desire, distress) that are inherently variable and difficult to quantify
• Placebo response rates in sexual dysfunction trials are typically high
• The clinical meaningfulness of the changes was supported by patient-reported outcomes and responder analyses
• The FDA considered the totality of evidence, including the consistent direction of effects across multiple endpoints, sufficient for approval

Safety in RECONNECT#

The most notable safety finding was the high rate of nausea:

The nausea was predominantly mild to moderate in severity, typically occurred within 1-2 hours of dosing, and tended to decrease with continued use. However, nausea was the most common reason for treatment discontinuation (8%).

Long-Term Safety Data#

52-Week Open-Label Extension#

Following the 24-week double-blind period, participants could continue into a 52-week open-label extension study. The long-term data demonstrated:

• Sustained efficacy with continued use over 52 weeks
• No new safety signals emerged with extended use
• Nausea remained the most common adverse event (40.4%) but was generally manageable
• Flushing (20.6%) and headache (12.0%) also continued to be reported
• The only severe treatment-related adverse event occurring in more than one participant was nausea

Blood Pressure Monitoring#

A key safety focus during clinical development was blood pressure effects. PT-141 produces transient increases in blood pressure and decreases in heart rate after each dose:

• Mean systolic increase: 1.9 mmHg (daytime ambulatory BP)
• Mean diastolic increase: 1.7 mmHg (daytime ambulatory BP)
• Changes typically resolve within 12 hours post-dose
• Individual blood pressure readings of 180/110 mmHg or higher occurred in approximately 1% of bremelanotide-treated patients
• The FDA label includes a recommendation to use with caution in patients at risk of cardiovascular disease

Neurobiological Mechanism Studies#

MC4R Pathway#

Pfaus et al. (2022) published a comprehensive review of bremelanotide's neurobiology in CNS Spectrums. The research identified the following mechanistic pathway:

1. Bremelanotide activates presynaptic MC4 receptors on neurons in the medial preoptic area (mPOA) of the hypothalamus
2. This stimulates release of dopamine (DA), an excitatory neurotransmitter central to sexual motivation
3. Dopaminergic signaling increases in key brain regions: nucleus accumbens (reward/motivation), medial preoptic area (sexual behavior integration), ventral tegmental area (dopamine source), arcuate nucleus (neuroendocrine control), and the medial and basolateral amygdala (emotional processing)
4. The result is increased sexual desire and motivation through modulation of the neural circuits governing the appetitive, motivational, and arousal aspects of sexual behavior

This central mechanism fundamentally distinguishes PT-141 from PDE5 inhibitors (which act peripherally on blood flow) and from flibanserin (which modulates serotonin/dopamine balance through 5-HT1A agonism and 5-HT2A antagonism).

Hormonal Effects#

Clinical studies have shown that bremelanotide administration produces small increases in circulating luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone levels. These hormonal changes suggest that MC4R activation has downstream effects on the hypothalamic-pituitary-gonadal axis, though the clinical significance of these small changes is unclear.

Male Sexual Dysfunction Research#

Early Clinical Data#

PT-141 was initially developed for both male and female sexual dysfunction. Phase 2 studies in men with erectile dysfunction demonstrated statistically significant improvements in erectile function compared to placebo. The mechanism in men is the same as in women: central MC4R activation increasing dopaminergic signaling.

Combination Therapy Approach#

Palatin Technologies has pursued a combination strategy for male ED, studying bremelanotide co-administered with PDE5 inhibitors. The rationale is that the central (PT-141) and peripheral (PDE5 inhibitor) mechanisms are complementary:

• PT-141 addresses the desire and motivation component (brain)
• PDE5 inhibitors address the erectile response (vascular)

This combination may be particularly relevant for men who do not respond to PDE5 inhibitor monotherapy, for whom a central arousal deficiency may be a contributing factor.

Evidence Quality Assessment#

The overall evidence quality for PT-141 is assessed as High, which is among the highest ratings for any peptide reviewed on this site:

Why High Evidence?#

PT-141's evidence rating reflects:

1. Two adequately powered Phase 3 RCTs meeting FDA registration standards
2. Statistically significant efficacy on coprimary endpoints in both studies
3. Comprehensive safety database from clinical development program
4. FDA approval based on benefit-risk assessment
5. Post-marketing surveillance providing real-world safety data
6. Well-characterized mechanism of action
7. Full human pharmacokinetic data

Research Gaps#

Despite the strong evidence base, several areas require further research:

1. Postmenopausal HSDD: Phase 3 trials only enrolled premenopausal women
2. Male sexual dysfunction: Phase 3 data needed for this indication
3. Comparative effectiveness: No head-to-head trial with flibanserin
4. Long-term safety: Data beyond 52 weeks limited
5. Combination therapy: Optimal combinations with other treatments not established
6. Biomarkers: No predictive biomarker for treatment response identified
7. Special populations: Limited data in cardiovascular disease, hepatic or renal impairment
8. Mechanism details: Full neural circuit characterization in humans incomplete

Related Reading#

• PT-141 overview and research guide
• PT-141 dosing protocols
• PT-141 molecular structure